◀ Back to EGFR
EGFR — SNX1
Protein-Protein interactions - manually collected from original source literature:
Studies that report less than 10 interactions are marked with *
-
IRef Biogrid Interaction:
EGFR
—
SNX1
(physical association, affinity chromatography technology)
Haft et al., Mol Cell Biol 1998
-
MIPS CORUM SNX complex (SNX1a, SNX2, SNX4, EGFR):
SNX complex (SNX1a, SNX2, SNX4, EGFR) complex (EGFR-SNX1-SNX2-SNX4)
Haft et al., Mol Cell Biol 1998
-
IRef Corum Interaction:
Complex of EGFR-SNX2-SNX4-SNX1
(association, coimmunoprecipitation)
Haft et al., Mol Cell Biol 1998
-
IRef Hprd Interaction:
SNX1
—
EGFR
(in vivo)
Kurten et al., Science 1996*, Haft et al., Mol Cell Biol 1998
-
IRef Hprd Interaction:
SNX1
—
EGFR
(two hybrid)
Kurten et al., Science 1996*, Haft et al., Mol Cell Biol 1998
-
IRef Ophid Interaction:
EGFR
—
SNX1
(aggregation, interologs mapping)
Brown et al., Bioinformatics 2005
Text-mined interactions from Literome
Okawa et al., Blood 2009
(Leukemia...) :
SNX-2112 inhibits cytokine induced
Akt and extracellular signal related kinase ( ERK ) activation and also overcomes the growth advantages conferred by interleukin-6, insulin-like growth factor-1, and bone marrow stromal cells
Bachleitner-Hofmann et al., Clin Cancer Res 2011
:
In all cell lines,
SNX-2112 led to degradation of MET, HER-2,
EGFR , and AKT, as well as abrogation of Ras/Raf/MEK/MAPK and PI3K/AKT signaling, followed by complete cell cycle arrest
Nishimura et al., Int J Oncol 2012
:
Silencing of
SNX1 by siRNA stimulates the ligand induced endocytosis of EGFR and
increases EGFR phosphorylation in gefitinib-resistant human lung cancer cell lines ... Further, western blot analysis revealed that silencing of
SNX1 expression by siRNA in the gefitinib-resistant cells
leads to an accelerated degradation of
EGFR along with a dramatic increase in the amounts of pEGFR after EGF stimulation ... Based on these findings, we suggest that
SNX1 is
involved in the negative regulation of ligand induced
EGFR phosphorylation and mediates EGFR/pEGFR trafficking out of early endosomes for targeting to late endosomes/lysosomes via the early/late endocytic pathway in human lung cancer cells